Long non-coding RNAs involved in retinoblastoma

Nasrolahi, Ava; Azizidoost, Shirin; Radoszkiewicz, Klaudia; Najafi, Sajad; Ghaedrahmati, Farhoodeh; Sheykhi-Sabzehpoush, Mohadeseh; Poodineh, Jafar; Hajizadeh, Maryam; Anbiyaiee, Amir; Farzaneh, Maryam; Feghhi, Mostafa

doi:10.1007/s00432-022-04398-z

Cited by 6 publications

(1 citation statement)

References 168 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The remaining genome consists of non-protein-coding regions, including numerous 'RNA only' genes, among which there is a large but diverse group called long non-coding RNAs or lncRNAs for short (Elkon and Agami, 2017;Dietlein et al, 2022;Paloviita and Vuoristo, 2022). Subsequent analyses have shown that lncRNAs fulfill various regulatory roles in healthy and cancerous tissues (Geng et al, 2018;Bi et al, 2019;Farzaneh et al, 2022a;Farzaneh et al, 2022b;Farzaneh et al, 2022c;Nasrolahi et al, 2022). As such, their expression and function are often altered in disease states (Kleinbrink et al, 2021;Yang et al, 2021;Anderson and Anderson, 2022;Dietlein et al, 2022;Erdogan et al, 2022) with selected examples now being used as diagnostic markers for various diseases including cancers (Li et al, 2019;Deng and Zou, 2022;Najafi et al, 2022;Zhang et al, 2022).…”

Section: Introductionmentioning

confidence: 99%

Clinical implications of lncRNA LINC-PINT in cancer

Bukhari

Khan

et al. 2023

Front. Mol. Biosci.

View full text Add to dashboard Cite

Long noncoding RNAs (lncRNAs) possess the potential for therapeutic targeting to treat many disorders, including cancers. Several RNA-based therapeutics (ASOs and small interfering RNAs) have gained FDA approval over the past decade. And with their potent effects, lncRNA-based therapeutics are of emerging significance. One important lncRNA target is LINC-PINT, with its universalized functions and relationship with the famous tumor suppressor gene TP53. Establishing clinical relevance, much like p53, the tumor suppressor activity of LINC-PINT is implicated in cancer progression. Moreover, several molecular targets of LINC-PINT are directly or indirectly used in routine clinical practice. We further associate LINC-PINT with immune responses in colon adenocarcinoma, proposing the potential utility of LINC-PINT as a novel biomarker of immune checkpoint inhibitors. Collectively, current evidence suggests LINC-PINT can be considered for use as a diagnostic/prognostic marker for cancer and several other diseases.

show abstract